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Abstract 
Background: Nosocomial outbreak due to carbapenem‑resistant Enterobacteriaceae has become serious challenge 
to patient treatment and infection control. We describe an outbreak due to a multidrug‑resistant Providencia rettgeri 
from January 2016 to January 2017 at a University Hospital in Seoul, Korea.
Methods: A total of eight non‑duplicate P. rettgeri isolates were discovered from urine samples from eight patients 
having a urinary catheter and admitted in a surgical intensive care unit. The β‑lactamase genes were identified using 
polymerase chain reaction and direct sequencing, and strain typing was done with pulsed‑field gel electrophoresis 
(PFGE).
Results: All isolates showed high‑level resistance to extended‑spectrum cephalosporins, aztreonam, meropenem, 
ertapenem, ciprofloxacin, and amikacin. They harbored the blaNDM‑1 carbapenemase and the blaPER‑1 type extended‑
spectrum β‑lactamases genes. PFGE revealed that all isolates from eight patients were closely related strains.
Conclusions: The 13‑month outbreak ended following reinforcement of infection control measures, including con‑
tact isolation precautions and environmental disinfection. This is the first report of an outbreak of a P. rettgeri clinical 
isolates co‑producing NDM‑1 and PER‑1 β‑lactamase.
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Background
The genus Providencia comprises part of the natural 
human gut flora but may also cause infections, includ-
ing travelers’ diarrhea, urinary tract infections, and other 
nosocomial infections [1]. Treatment of these infections 
is challenging because Providencia rettgeri strains are 
intrinsically resistant to many antimicrobials including 
ampicillin, first generation cephalosporins, polymyx-
ins and tigecycline [2]. Furthermore, in recent years P. 
rettgeri has become increasingly important because of 
the emergence of carbapenemase-producing strains [3, 
4]. Carbapenemases are enzymes known to hydrolase 
almost all types of β-lactams [5]. The New Delhi metallo-
β-lactamase (NDM-1) has been firstly identified in 2009 
in a Swedish patient who had been previously hospital-
ized in New Delhi, India [6]. The first occurrence of 
NDM-1 producers was reported in clinical isolates of P. 
rettgeri in Israel in 2013 [7]. Since then, other cases have 
been reported in Mexico, Brazil, Argentina, Ecuador, 
Canada, and Nepal [3, 4, 8–13].
PER-1 enzyme is belong to class A extended-spectrum 
β-lactamases (ESBLs) and firstly discovered in a plasmid 
of Pseudomonas aeruginosa in France [14]. Later, it has 
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also found among several Gram-negative species includ-
ing Acinetobacter baumannii, Salmonella enterica sero-
var Typhimurium, and also in P. rettgeri [15, 16]. PER-1 
is widely spread in Turkey, however, high prevalence of 
PER-1 ESBL in A. baumannii has been reported in Korea 
[17].
Here, we report the first outbreak of multidrug-resist-
ant P. rettgeri strain co-producing NDM-1 and PER-1 in 
Korea.
Materials and methods
Patients and bacterial isolates
From January 2016 to January 2017, a total of eight P. 
rettgeri isolates from eight patients were included in this 
study. Bacterial identification was done with a Vitek-MS 
(bioMérieux, Marcy I’Etoile, France). Medical records 
of the patients were retrospectively reviewed. This study 
protocol was approved by the hospital institutional 
review board.
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) for cefo-
tetan, cefotaxime, ceftazidime, cefepime, ertapenem, 
imipenem, meropenem, aztreonam, amikacin, ciproflox-
acin, gentamicin, and tigecycline were determined using 
Etest strips (bioMérieux) on the Mueller–Hinton agar 
(Becton–Dickinson, Sparks, MD, USA). Colistin MIC 
was determined by broth microdilution. When available, 
antimicrobial susceptibility was interpreted based on 
the Clinical and Laboratory Standards Institute (CLSI) 
guideline [18]. For tigecycline and colistin, the Euro-
pean Committee for Antimicrobial Susceptibility Testing 
(EUCAST) criteria were used [19].
Detection of β‑lactamase genes
The carbapenemase genes and ESBL genes were detected 
using specific PCR primers (Table  1) [20–27]. Ampli-
fied products were directly sequenced on the ABI 
3730xl automatic sequencer (Applied Biosystems, Fos-
ter City, CA, USA) using the same primer pair. The 
sequences obtained were compared to those in GenBank 
Table 1 Primers used in this study for identifying antimicrobial resistance genes
Classification Primer Target Nucleotide sequence, 5′ to 3′ Product size, bp References
Class A β lactamases VEB‑1F blaVEB CGACTTCCATTTCCCGATGC 642 [20]
VEB‑1R GGACTCTGCAACAAATACGC
PER‑1F blaPER‑1 ATGAATGTCATTATAAAAGCT 927 [20]
PER‑1R TTAATTTGGGCTTAGGG
CTX‑M‑1F blaCTX‑M‑1 GCAGCACCAGTAAAGTGATGG 591 [21]
CTX‑M‑1R GCTGGGTGAAGTAAGTGACC
CTX‑M‑825F blaCTX‑M‑8 CGCTTTGCCATGTGCAGCACC 307 [22]
CTX‑M‑825R GCTCAGTACGATCGAGCC
CTX‑M‑914F blaCTX‑M‑9 GCTGGAGAAAAGCAGCGGAG 474 [22]
CTX‑M‑914R GTAAGCTGACGCAACGTCTG
SHV‑OS5 blaSHV TTATCTCCCTGTTAGCCA 797 [23]
SHV‑OS6 GATTTGCTGAATTCGCTC
TEM‑A blaTEM TAAAATTCTTGAAGACG 1074 [23]
TEM‑B TTACCAATGCTTAATCA
KPC‑F blaKPC ATGTCACTGTATCGCCGTCT 893 [24]
KPC‑R TTTTCAGAGCCTTACTGCCC
Class B β lactamases VIM‑F blaVIM GATGGTGTTTGGTCGCATA 390 [25]
VIM‑R CGAATGCGCAGCACCAG
IMP‑F blaIMP GGAATAGAGTGGCTTAATTC 232 [26]
IMP‑R TCGGTTTAATAAAACAACCACC
NDM‑1‑F blaNDM‑1 CAATATTATGCACCCGGTCG 726 [27]
NDM‑1‑R ATCATGCTGGCCTTGGGGAA
Class D β lactamases OXA‑10F blaOXA‑10 TATCGCGTGTCTTTCGAGTA 760 [20]
OXA‑10R TTAGCCACCAATGATGCCC
OXA‑F blaOXA‑48 GCGTGGTTAAGGATGAACAC 438 [26]
OXA‑R CATCAAGTTCAACCCAACCG
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(www.ncbi.nlm.nih.gov/GenBank) using the BLAST pro-
gram (www.ncbi.nlm.nih.gov/BLAST/).
Pulsed‑field gel electrophoresis
The bacterial genetic relatedness was evaluated by 
Pulsed-field gel electrophoresis (PFGE). Genomic DNA 
was digested with SfiI enzyme, and DNA fragments 
were separated on a CHEF-DRII System (Bio-Rad, Her-
cules, CA, USA). A lambda ladder (Bio-Rad) was used 
as a DNA size marker. The band patterns were analyzed 
using UVIband/Map software (UVItech Ltd., Cambridge, 
UK) and the dendrograms were generated based on the 
unweighted pair group method using arithmetic averages 
from the Dice coefficient. Isolates that exhibited a PFGE 
profile with more than 90% similarity (pulsotype) were 
considered as closely related strains.
Results
The characteristics of these patients and antimicrobial 
susceptibility patterns of P. rettgeri isolates were sum-
marized in Table 2. In total, eight P. rettgeri isolates were 
recovered from urine samples of eight patients admitted 
in a surgical intensive care unit (SICU). All patients were 
admitted to a SICU from hospitalization and had a uri-
nary catheter. The median days of the SICU stay before 
P. rettgeri isolation was 21.5  days (range, 8–38  days) 
(Fig. 1). All patients except one (P5) were recovered and 
discharged during the outbreak. A patient (P5) died fol-
lowing Enterococcus faecalis bacteremia. All P. rettgeri 
isolates showed similar antibiogram with high MIC lev-
els to various classes of antimicrobial agents tested (cefo-
tetan, cefotaxime, ceftazidime, cefepime, azteronam, 
meropenem, ertapenem, ciprofloxacin, amikacin, and 
tigecycline). Imipenem MICs were 0.5–4 μg/mL (6/8 sus-
ceptible isolates, 1/8 intermediate isolate, and 1/8 resist-
ant isolate) and gentamicin MICs were 8–16 μg/mL (4/8 
intermediate isolates and 4/8 resistant isolates). Molecu-
lar testing revealed that all the P. rettgeri isolates were 
positive for blaNDM-1 and blaPER-1. No amplicons were 
observed for the other primer pairs for blaVEB, blaCTX-
M-1, blaCTX-M-8, blaCTX-M-9, blaSHV, blaTEM, blaKPC, blaVIM, 
blaIMP, blaOXA-10, and blaOXA-48. PFGE revealed that all 
isolates closely related one pulsotype with > 90% similar-
ity (Fig. 2). The eight isolates had the three kinds of den-
drogram patterns.
Discussion
In the present study we reported and characterized an 
outbreak of blaNDM-1 and blaPER-1 carrying P. rettgeri. 
All patients were admitted to the same SICU and had a 
urinary catheter. P. rettgeri is well known to be isolated 
from urine of hospitalized and catheterized patients 
[16]. Although periods of hospitalization of our patients 
were not completely overlapping, PFGE revealed that all 
isolates were closely related. This suggests clonal cross-
transmission of this strain in the SICU, and there is a 
possibility of transmission between patients and medical 
personnel by hand colonization or by environmental con-
tamination. Infection control measures were reinforced 
in the SICU to include extensive environmental disin-
fection, active screening for carbapenemase-producing 
Enterobacteriaceae, and exhaustive contact isolation pre-
cautions. The outbreak did not eradicate in a short time, 
but the outbreak was eventually interrupted in January 
2017.
Carbapenem resistance in Enterobacteriaceae has 
become a major public health challenge [28]. While car-
bapenem is a drug of choice for treatment of Entero-
bacteriaceae producing ESBL and plasmid-mediated 
AmpC cephalosporinase, production of carbapenemase 
in Enterobacteriaceae can be emerged. Carbapenemase 
gene is important due to its potential transferability to 
other species, by plasmids and transposons [28]. NDM-1 
encoding plasmids are diverse and can also carry other 
antimicrobial resistance genes, including carbapenemase 
genes, ESBL genes, plasmid-mediated cephalosporinase 
genes, and aminoglycoside resistance genes [28, 29]. 
Among these, most ESBLs found with NDM-1 have been 
reported to be as CTX-M-15 type [29, 30]. Until now, 
this is the first report of Enterobacteriaceae co-carrying 
NDM-1 and PER-1 type ESBL. Although the NDM-1 
enzyme is known to inactivate all β-lactams except 
aztreonam [6], our P. rettgeri isolates showed high MIC 
to aztreonam, possibly due to production of PER-1 type 
ESBL. The range of MIC to imipenem revealed 0.5–4 μg/
mL. Imipenem MICs for Providencia spp. tend to be 
higher (e.g., MICs in the intermediate or resistant range) 
naturally. These isolates may have elevated imipenem 
MICs by mechanisms other than production of carbap-
enemases [18].
It is known that the multidrug-resistant bacteria have 
superior ability to survive and spread successfully in a 
hospital environment. In addition, the patient’s risk fac-
tor is also responsible for the nosocomial transmission of 
multidrug-resistant bacteria. Patient’s underlying disease, 
exposure to antimicrobial agents, and history of hav-
ing invasive procedures are known as risk factors for the 
acquisition of carbapenem-resistant Enterobacteriaceae 
[28]. This outbreak persisted for 13  months, although 
the prompt infection control strategy was initiated after 
recognition of the first few cases. Because ICU admission 
patients often have one or more of risk factors, so it could 
be very difficult to eradicate once the outbreak occurs.
In conclusion, we report an alarming outbreak of 
high-level of multidrug-resistant P. rettgeri isolates co-
producing NDM-1 and PER-1 β-lactamases. Infection 
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prevention and control efforts should be continuously 
made to prevent nosocomial transmission of these 
threatening bacteria.
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